Business Context and Reporting Period
Company: cbdMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 8, 2021
Reporting Period: Event date January 8, 2021
Business Context: The registrant is an emerging growth company incorporated in North Carolina. Its common stock (YCBD) and 8% Series A Cumulative Convertible Preferred Stock (YCBD PR A) are listed on the NYSE American.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a corporate governance event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The primary material event reported is the Board of Directors' approval of the 2021 Equity Compensation Plan (the "2021 Plan") on January 8, 2021. Key details include:
- Share Reserve: 5,000,000 shares of common stock reserved for issuance.
- Evergreen Provision: Starting October 1, 2022, the share reserve will automatically increase annually by 1% of outstanding shares (as of September 30), capped at 250,000 shares per year.
- Shareholder Approval: The plan requires shareholder approval at the 2021 annual meeting (expected March 2021).
- Grant Restrictions: While grants may be made prior to shareholder approval, they will not vest or become exercisable until approval is obtained. No grants will be made to executive officers or directors until shareholder approval and NYSE Regulation approval are secured.
Guidance, Outlook, and Risks
Management Commentary: The stated purpose of the 2021 Plan is to attract, retain, and motivate highly qualified personnel essential to the company's success.
Plan Administration: The Compensation, Corporate Governance and Nominating Committee will administer the plan, determining grant terms, exercise prices, and vesting schedules.
Risks and Contingencies:
- ISO Validity: If shareholder approval is not obtained by January 8, 2022, Incentive Stock Options (ISOs) cannot be awarded. Any ISOs previously granted will automatically convert to Non-Statutory Stock Options (NSOs).
- Exercise Price: Options must be granted at no less than 100% of fair market value (110% for ISOs granted to 10% shareholders).
- Term: The plan will terminate 10 years from the date of adoption unless suspended or terminated earlier by the Board.
Investor Verification Checklist
- Verify the outcome of the shareholder vote on the 2021 Plan at the March 2021 annual meeting.
- Confirm NYSE Regulation approval of the Additional Listing Application for the reserved shares.
- Monitor the "evergreen" share increase mechanism starting in 2022 to assess potential dilution.
- Review the full text of the 2021 Plan (Exhibit 10.1) for specific vesting schedules and performance criteria not detailed in this summary.